ESR1 and breast cancer: The gene expression-defined basal-like breast cancer subtype is currently clinically approximated by triple-negative immunohistochemical (IHC) status, characterized by combined negativity for estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor-2 (Her2).